Idera Pharmaceuticals (IDRA) Jumps: Stock Rises 13.7%
Idera Pharmaceuticals, Inc. IDRA was a big mover last session, as the company saw its shares rise nearly 14% on the day. The upside came after the company presented positive data from Phase 1/2 clinical trial for IMO-8400. This led to far more shares changing hands than in a normal session, breaking the recent trend of the company, as the stock is now trading above the volatile price range of $3.19 to $3.89 over the past one month time frame.
The stock has witnessed one upward estimate revisions in the past 30 days. The Zacks Consensus Estimate has also moved up over the same time frame, suggesting that more solid trading could be ahead for Idera Pharmaceuticals. So make sure to keep an eye on this stock going forward to see if the latest jump can turn into more strength down the road.
Idera Pharmaceuticals carries a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%.
A better-ranked stock in the med-biomed/gene industry is Achillion Pharmaceuticals, Inc. ACHN, sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Is IDRA going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
IDERA PHARMACT (IDRA): Free Stock Analysis Report
ACHILLION PHARM (ACHN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
